Amgen will now move ahead with a phase 2 programme for AMG 133, as it tries to enter a weight-loss category that has been transformed by the approval of Novo Nordisk’s once-weekly GLP-1 agonist ...

Investing.com -- Shares of Amgen (NASDAQ: NASDAQ ... MariTide (formerly AMG 133). While the study demonstrated notable weight-loss potential, investor expectations for the drug's efficacy may ...

Amgen's Uplizna Shows Improved Symptoms In Patients With Muscle Weakness Disorder Over One Year Amgen's Uplizna met key endpoints in a Phase 3 gMG trial, showing sustained efficacy and improvement ...

Amgen (AMGN) is one of the stocks most watched by Zacks.com visitors lately. So, it might be a good idea to review some of the factors that might affect the near-term performance of the stock.